NSR、科学通报、Science Bulletin：每年刊登 2篇左右高争议论文 吧！ 建议《国家科学评论 NSR， National Science Review》、《科学通报 Chinese Science Bulletin》和《Science Bulletin》，设立“前瞻”栏目，平均每年刊登 2篇左右的“高争议”论文 吧！限制该类论文篇幅在 1~3 页。 日本本世纪19年19个诺贝尔科学奖。 我国诺贝尔科学奖将在2070年左右开始出现“井喷”现象。按照目前的状态，诺贝尔科学奖大多数获奖的时间滞后超过了20年。所以，我们现在就要为“ 我国将来的诺贝尔科学奖 ”成果 大开绿灯！ 赫胥黎说：“历史告诫我们说， 一种崭新的真理惯常的命运是： 始于异端，终于迷信。 ” Thomas Huxley：It is the customary fate of new truths, to begin as heresies, and to end as superstitions. History warns us that it is the customary fate of new truths to begin as heresies and to end as superstitions. https://www.brainyquote.com/quotes/thomas_huxley_403887 例如，1905年的爱因斯坦“奇迹年”： “而在这之前，爱因斯坦博士论文的后续工作，即关于布朗运动的论文5月11日已经被Annalen der Physik杂志收到，当年发表。这是1905年他完成的第三篇文章。8月，爱因斯坦将博士论文投给同一杂志，次年发表。他1905年的另外三篇文章是：第一篇关于光量子假说，第四篇关于狭义相对论，第五篇关于相对论质能关系。全部发表在 Annalen der Physik 。 当时该刊拒稿率只有百分之几。 ”“ 而作为理论编辑的普朗克（M. Planck）是很宽容的。 ” “ 该刊拒稿率只有百分之几。 ”是保证1905年爱因斯坦“奇迹年”的核心因素。 假如爱因斯坦被吹毛求疵的审稿人要求稿件改来改去，1905年奇迹年肯定不存在了。 实际上，爱因斯坦的这些论文有不少瑕疵。爱因斯坦自己后来也是改来改去。 日本本世纪19个诺贝尔科学奖，最多时一年有3人获奖。假如NSR、科学通报、Science Bulletin 平均每年刊登2篇左右高争议论文，则每年一共有6项左右的高争议观点或结果发表。希望能把未来中国诺贝尔科学奖的一半成果给包揽过来。 这些“前瞻”栏目论文，不采用通常的同行评审，而采用针对性的个性化的特殊评审。 审稿过程要保证那些真正的原创工作得以 及时刊登 ， 而不要吹毛求瑕，不要“捡了芝麻，丢了西瓜”，不要“只见树木，不见森林”，不要“明察秋毫之末，而不见舆薪”。 “科学文化的历史积淀不够，科学价值观存在一定偏差，科学原创自信心尚显不足”，要在稿件评审中予以纠正。 年刊登出的论文数量： （1）National Science Review 130篇/年， （2）Chinese Science Bulletin 600篇/年， （3）Science Bulletin 272篇/年。 所以，每年“前瞻”栏目刊登“2篇左右高争议论文”，基本上不会影响到整个期刊的各种量化评价指标。 何况“2篇左右高争议论文”的引用，不一定会很低。 说不定会被“热骂”得引用量奇高呢！！ 参考资料： 孟津，2018-10-09，《国家科学评论》IF奔10 去以后的路 精选 http://blog.sciencenet.cn/blog-4699-1139752.html 赵明，2018-10-03，日本18年里18人拿了诺贝尔奖，是否真的可怕？ 精选 http://blog.sciencenet.cn/blog-40615-1138658.html 18 人的获奖工作有 17 人是在上世纪最后 30 年完成的。只有生理学或医学奖得主山中伸弥的工作是 2005 年左右完成的。 科学网，2014-04-10，《自然》文章：时间滞后将威胁诺奖地位 http://news.sciencenet.cn/htmlnews/2014/4/291709.shtm 诺贝尔奖候选人常常需要等上20多年才能得到这个科学上的最高荣誉。 Benjamin F. Jones, Bruce A. Weinberg. Age dynamics in scientific creativity. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 2011, 108(47): 8910-18914 (NOV 22 2011) http://www.pnas.org/content/108/47/18910.full http://www.pnas.org/content/108/47/18910/suppl/DCSupplemental 2016-10-07，诺贝尔奖：出成果的年龄（已知）与发表的期刊（未知） http://blog.sciencenet.cn/blog-107667-1007183.html 刘庆宽，2019-10-11，又有日本人获诺奖！扒一扒这所诺奖最多的大学 精选 http://blog.sciencenet.cn/blog-63255-1201481.html 2016-11-29,爱因斯坦被拒授过博士学位和副教授职位吗？ https://baike.baidu.com/tashuo/browse/content?id=d986c0a0c01279765d6878f0 爱因斯坦博士论文的后续工作，即关于布朗运动的论文5月11日已经被Annalen der Physik杂志收到，当年发表。这是1905年他完成的第三篇文章。8月，爱因斯坦将博士论文投给同一杂志，次年发表。他1905年的另外三篇文章是：第一篇关于光量子假说，第四篇关于狭义相对论，第五篇关于相对论质能关系。全部发表在 Annalen der Physik 。 当时该刊拒稿率只有百分之几。 施郁，2016-02-14，从引力波谈爱因斯坦的幸运 精选 http://blog.sciencenet.cn/blog-4395-956018.html 而1905年的爱因斯坦恰恰曾幸运地因为德国《物理学年鉴(Annalen der Physik)》的宽松而得以在该杂志发表5篇改变物理学的论文，特别是看上去离经叛道的光量子和狭义相对论论文。 当时该杂志的拒稿率只有百分之几 ，而作为理论编辑的普朗克（M. Planck）是很宽容的。 科学网，2008-11-13，《探索》杂志：爱因斯坦一生中的23个错误 http://news.sciencenet.cn/htmlnews/2008/11/213197.html 1.1905年：爱因斯坦根据狭义相对论，在计算时钟同步过程上出现错误； 2.1905年：错误估计迈克逊—莫利实验； 3.1905年：在高速粒子的横向质量计算上出现错误； 4.1905年：爱因斯坦在运用数学和物理知识计算液体粘性时多次出现错误。爱因斯坦通过计算液体的粘性，推导出分子的大小； 5.1905年：在热辐射和光量子关系的认识上出现错误； 6.1905年：首次验证质能方程E=mc2时出现错误； 中国科学院，2014-05-26，中国科学院学部主席团发布《追求卓越科学》宣言 http://www.cas.cn/xw/zyxw/yw/201405/t20140525_4126367.shtml 中国科学要走向卓越，仍然面临严峻的挑战。 科学文化的历史积淀不够，科学价值观存在一定偏差，科学原创自信心尚显不足 ，正在成为制约中国科学走向卓越的深层次因素。目前，我国科学界浮躁现象比较严重，科学精神缺失、失范甚至不端行为屡有发生，都与追求卓越科学的价值理念相对薄弱、激励卓越科学的体制机制不够完善有关。 感谢您的指教！ 感谢您指正以上任何错误！ 感谢您提供更多的相关资料！
We are pleased to announce that Chinese Science Bulletin will be officially renamed Science Bulletin from January 2015. Science Bulletin will be a semi-monthly journal with professional, rapid review and editorial decision. We will publish articles on a wide range of topics including Life Medical Sciences, Earth Sciences, Physics (Mechanics Astronomy), Chemistry, Materials Sciences, Engineering Sciences, and those of interdisciplinary sciences. We appreciate your cooperation in this matter and look forward to your continued support. Welcome to submit your manuscripts to Science Bulletin ( Sci. Bull. ) . Editorial Office Chinese Science Bulletin July, 2014
If you cannot see this message please view here Home Independence Subscriptions Archive In the news Dear Prof Xu Peiyang, You might be interested to know that February's issue of Drug and Therapeutics Bulletin (DTB) includes the article A change of units for HbA1c . Worldwide, measurement of glycated haemoglobin (HbA1c) is the mainstay for monitoring long-term glycaemic control in people with diabetes mellitus. Recently, a new internationally agreed standard for measuring and reporting HbA1c levels was agreed by the International Federation of Clinical Chemistry (IFCC). From 1 June 2009 all UK laboratories began reporting HbA1c in the new units according to this standard. This article explains the rationale behind this change. A change of units for HbA1c is available online for DTB subscribers, or for non-subscribers to purchase via pay-per-view. Also in the February issue: Patient safety first? This months editorial highlights the potential adverse effects on patient safety of the long-awaited switch of the management of pharmaceutical policy from the ECs Enterprise and Industry directorate to its Health and Consumer Policy directorate (known as DG SANCO). Management of community-associated MRSA This article discusses the management of patients with community-associated MRSA (CA-MRSA). ▼Pregabalin for generalised anxiety disorder This article reviews the role of ▼Pregabalin (Lyrica Pfizer) in the management of patients with generalised anxiety disorder (GAD). Make DTB your reference point with the complete online archive DTB personal and practice subscribers have unlimited access to the conveniently searchable archive which now includes all articles back to the very first issue - in all 47 years of articles. Alternatively, articles are available to purchase via pay-per-view. Subscribe today! DTB is rated one of the top two most useful and objective information sources on prescribing*. For your key source of practical, unbiased and independent prescribing advice, subscribe to DTB today. DTB is published monthly and an online only subscription is less than 2 / $3 / 2 per week (excluding taxes). Don't miss out on this critical publication. For more information, please visit dtb.bmj.com/subscriptions. Alternatively, please contact our Customer Services team by emailing subscriptions@bmjgroup.com or telephone +44 (0)20 7383 6270. We look forward to hearing from you. Best wishes Dr Ike Iheanacho Editor Drug and Therapeutics Bulletin (DTB) *National Audit Office, Prescribing costs in primary care, 2007 About BMJ Group Privacy policy Terms and conditions Contact us The BMJ Group is one of the world's most trusted providers of medical information for doctors, researchers, health care workers and patients www.bmjgroup.bmj.com. The recipient should check this email and attachments for viruses because the BMJ Group accepts no liability for any damage caused by viruses. Emails sent or received by the BMJ Group may be monitored for size, traffic, distribution and content. Use of our content is governed by our website terms and conditions http://group.bmj.com/group/about/legal/terms . BMJ Publishing Group Limited trading as BMJ Group. A private limited company, registered in England and Wales under registration number 03102371. Registered office: BMA House, Tavistock Square, London WC1H 9JR, UK. If you do not wish to receive these emails in future please unsubscribe here . Your unsubscribe request may take up to five working days to process.
If you cannot see this message please view here Home Independence Subscriptions Archive In the news Dear Prof Xu Peiyang, You might be interested to know that January's issue of Drug and Therapeutics Bulletin (DTB) is now published and available online. DTB a publication rated one of the top two most useful and objective information sources on prescribing * covers the following topics this month: More on high street mole checks In an editorial and an accompanying podcast in March 2009, we highlighted issues about 'high street mole clinics'. These included concerns that new imaging technologies might be used in such clinics by clinicians lacking appropriate training. In this editorial, we discuss some developments in this area. Management of medication overuse headache Headache is one of the most frequent reasons for medical consultation in both general practice and specialist neurology clinics. Prescribed and over-the-counter medications are taken to alleviate headaches, but may be used incorrectly. Overuse of these can result in medication overuse headache (MOH). In this article, we review the management of MOH. Cognitive behavioural therapy for schizophrenia Around 0.7% of the population have schizophrenia. This serious psychotic disorder affects psychological and social functioning, and diagnosis can lead to stigma. Pharmacological interventions are a key element in management, but are sometimes ineffective and nearly half of patients do not adhere to drug treatment. In this article, we consider cognitive behavioural therapy as adjunctive treatment in the management of patients with schizophrenia. ▼Tocilizumab for rheumatoid arthritis ▼Tocilizumab (RoActemra) is a new biological agent available in the UK for the treatment of adults with rheumatoid arthritis. Unlike currently available biological agents, the drug targets the pro-inflammatory cytokine interleukin-6 (IL-6). In this article, we consider the place of tocilizumab in rheumatoid arthritis and whether it offers any advantages over other treatments. Make DTB your reference point with its now complete online archive All 47 years of rigorous and independent articles are now available for DTB subscribers, or for non-subscribers to purchase via pay-per-view. Subscribers also have unlimited access to the conveniently searchable online articles. Subscribe today! For your key source of practical, unbiased and independent prescribing advice, subscribe to DTB today. DTB is published monthly and an online only subscription is less than 2 / $3 / 2 per week (excluding taxes). Don't miss out on this critical publication. For more information, please visit dtb.bmj.com/subscriptions. Alternatively, please contact our Customer Services team by emailing subscriptions@bmjgroup.com or telephone +44 (0)20 7383 627. We look forward to hearing from you. Best wishes
标签: Bulletin
